Screener
Perspective Therapeutics CATX Total Cost of Revenue
Discontinued — last reported Q3 '23
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Perspective Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Perspective Therapeutics’s 10-Q, filed November 14, 2023.
- Filed
- Nov 14, 2023, 4:59 PM EST
- Fiscal quarter
- Q3 FY2023
- Calendar quarter
- Q3 2023
- Accession
- 0001437749-23-032036
| Line item | Three months ended / September 30, 2023 | Three months ended / September 30, 2022 | Nine months ended / September 30, 2023 | Nine months ended / September 30, 2022 |
|---|---|---|---|---|
| Sales, net | $1,909 | $$1,717 | $5,239 | 7,132 |
| Grant revenue | 276 | - | 1,097 | - |
| Total revenue | 2,185 | 1,717 | 6,336 | 7,132 |
| Cost of sales | 1,447 | 1,303 | 4,863 | 4,351 |
| Gross profit | 738 | 414 | 1,473 | 2,781 |
| Operating expenses: | ||||
| Research and development | 5,721 | 708 | 15,231 | 2,053 |
| Sales and marketing | 855 | 800 | 2,578 | 2,141 |
ITEM 1 - FINANCIAL STATEMENTS
FAQ
- What is Perspective Therapeutics's total cost of revenue?
- Perspective Therapeutics (CATX) reported total cost of revenue of $1.45M in Q3 2023.
- How has Perspective Therapeutics's total cost of revenue changed year-over-year?
- Perspective Therapeutics's total cost of revenue increased by 11.1% year-over-year, from $1.3M to $1.45M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about Perspective Therapeutics's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude